Vera Therapeutics (VERA) Common Equity (2020 - 2026)

Vera Therapeutics has reported Common Equity for 7 years, with the latest figure at $499.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 6.6% year-over-year to $499.7 million; the trailing twelve-month figure through Mar 2026 stood at $499.7 million (down 6.6% YoY), and the FY2025 full-year result was $604.5 million, up 4.74% from the prior year.
• Common Equity for Q1 2026 stood at $499.7 million, down from $604.5 million in the prior quarter.
• The five-year high for Common Equity was $604.5 million in Q4 2025, with the low at $76.9 million in Q4 2022.
• Historically, Common Equity has averaged $295.1 million across 5 years, with a median of $289.1 million in 2024.
• Annual changes were most pronounced in 2024 — Common Equity soared 467.59% — and 2026, when it dropped 6.6%.
• Vera Therapeutics' Common Equity stood at $76.9 million in 2022, then soared by 32.22% to $101.7 million in 2023, then soared by 467.59% to $577.2 million in 2024, then grew by 4.74% to $604.5 million in 2025, then decreased by 17.34% to $499.7 million in 2026.
• The last three Common Equity figures came in at $499.7 million (Q1 2026), $604.5 million (Q4 2025), and $398.9 million (Q3 2025), per Business Quant data.